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estimate the ratio of incremental expected cost of ramipril
therapy to the incremental life year gained (LYG). All
costs were discounted at 3% per year. RESULTS: Dis-
counted cost for within-trial CE analysis was $2600 for
ramipril compared to $1554 for placebo (incremental
cost, $1046). With a 2% absolute risk reduction in
within-trial cardiac mortality, the incremental cost/LYG
was $11,622. Cost/LYG under the persistent beneﬁt was
$4509. For extended beneﬁt of therapy, cost/LYG was
$4014. Sensitivity analysis ranged from cost/LYG of
$3143 to $12,689. CONCLUSIONS: Ramipril is CE in
preventing CV events in high-risk patients across multi-
ple therapy beneﬁt scenarios.
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OBJECTIVES: To estimate hospital costs and charges
attributable to the development of acute renal insufﬁ-
ciency (ARI) and acute renal failure (ARF) after coronary
artery bypass grafting (CABG). METHODS: A retro-
spective analysis of patients undergoing CABG at Uni-
versity of Pittsburgh Medical Center from June 1998
through May 2002 was conducted. Patients were
matched with respect to severity of illness by APACHE
III scores. A Wilcoxon signed-rank test was used to assess
differences in costs and charges. RESULTS: There were
3741 total patients that resulted in 644 matched pairs.
The mean and median hospital charges among cases were
approximately $221,864 and $158,312 respectively. The
mean and median hospital charges among controls were
approximately $110,868 and $91,738 respectively. Dis-
tribution of the hospital charges were positively skewed
(Shapiro-Wilk test, 0 < 0.001). The difference in median
hospital charges was $66,500 (Wilcoxon signed-rank test,
p < 0.01). The mean and median hospital costs among
cases were $44,180 and $28,901 respectively. The mean
and median hospital costs among controls were $22,471
and $18,038 respectively. The difference in median hos-
pital costs was $10,863 (Wilcoxon signed-rank test, p <
0.01). The mean and median ICU costs among cases were
$35,566 and $21,183 respectively. The mean and median
ICU costs among controls were $17,634 and $13,655
respectively. The difference in median ICU costs was
$7528 (Wilcoxon signed-rank test, p < 0.01). CONCLU-
SIONS: Although patients were matched using APACHE
III scores, a severity of illness scoring system, patients
with ARI/ARF after CABG had signiﬁcantly higher hos-
pital and ICU costs and charges than patients without
ARI/ARF. These differences can be attributed to the devel-
opment of renal complications after CABG.
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Sudden death is one of the two main causes of mortality
in congestive heart failure. Implanted cardioverter deﬁb-
rillator (ICD) is an expensive but highly effective treat-
ment in preventing sudden death. The gain of primary
prophylactic ICD in preventing sudden death in heart
failure has not been clearly established. OBJECTIVE:
Compare the cost-effectiveness of prophylactic ICD with
conventional treatment for preventing sudden death.
METHODS: A lifetime decision model was built. The
perspective is societal. The target population is U.S. HF
patients, aged 60, with NYHA functional Class II and III.
Estimates of cost, utility and probabilities are taken from
literature, clinical experts, CMS fee schedule payment,
and the Bureau of Labor Statistics. In all cases, we assume
that ICD is effective in preventing all sudden death, and
the ICD would be reimplanted at ninth year. In our base
case, we assume that total annual mortality rate is 20%,
of which sudden death accounts for 40%; the utility of
ICD is 10% less during the 1st year after implantation,
and reverts back to pre-implantation level in the 2nd year.
We did a one-way sensitivity analyses on all model para-
meters. RESULTS: the lifetime cost is $117,095 for
patients with prophylactic ICD and $24,709 for patients
with conventional treatment in 2002; the QALYs gained
were 2.9088 and 1.9045 respectively. The CE ratio was
$91,990 per QALY saved. We failed to show that ICD is
cost-effectiveness under any plausible scenario if we use
$50,000 per quality-adjusted-life-year saved as the cut-off
point. CE ratio is sensitive to the utility at the second 
and subsequent years after ICD implantation, and the
proportion of sudden death in all HF-related deaths.
CONCLUSIONS: Using conventional cost effectiveness
benchmarks of $50,000 per life year saved, it is unlikely
that ICD would be cost-effectiveness in preventing sudden
death compared to conventional treatment for heart
failure patients. Future research should focus on patient
utility with and without ICD.
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OBJECTIVES: Previous studies have used Markov
models to predict future CHF hospitalizations based on
